SILVER SPRING, Md., Feb. 22, 2024 (GLOBE NEWSWIRE) — Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that it will release its fourth quarter and full year 2023 financial results after market close on...
SILVER SPRING, Md., Jan. 10, 2024 (GLOBE NEWSWIRE) — Elutia Inc. (Nasdaq: ELUT) today announced that it has regained compliance with Nasdaq’s market value of listed securities requirement and majority independent board requirement. As a result, the Company now...
510(k) filing follows FDA feedback from successful pre-submission meeting SILVER SPRING, Md., Dec. 18, 2023 (GLOBE NEWSWIRE) — Elutia Inc. (Nasdaq: ELUT) today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration...
– Company Now Focused on Proprietary Drug-Eluting Biomatrix Platform – SILVER SPRING, Md., Nov. 09, 2023 (GLOBE NEWSWIRE) — Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced it completed the...
Enter your information and we will be in touch with you.
News Sign Up
Sign up to receive news notifications.
Connect With a Rep
Enter your information and we will be in touch with you.
Learn More Today
Fill out the form below for more information.
Webinar Signup
Sign up to receive webinar notifications.
We use cookies to ensure that we give you the best experience on our website. More information about our site Terms of Use and Privacy Policy provide additional details. Continue on to our site only if you agree with these policies.
